India's Largest Study On Drug Tocilizumab To Treat Severe Covid Patients
India's first multicentre randomised controlled trial on the use of the drug Tocilizumab in Covid patients has demonstrated that an anti-inflammatory treatment reduces the risk of death among patients with severe COVID-19. The results of the trial were published this morning in one of the world's top journals, 'The Lancet Respiratory Medicine'. We spoke with the lead researcher, Dr Arvinder Singh Soin.
